CELEBRATING MORE REBIRTHDAYS WITH HEARTMATE™ II LEFT VENTRICULAR ASSIST DEVICE
Experience makes a difference. To date, over 25,000 heart failure patients have received the HeartMate II™ LVAD. Many have passed the 5-year milestone on therapy, with some still on therapy after 10-plus years—living proof for over a decade that HeartMate II delivers predictable surgical and clinical performance for improved outcomes.
80% OF HEARTMATE II LVAD RECIPIENTS REVERSE THE SYMPTOMS OF THEIR HEART-FAILURE CONDITIONS.
EXPERIENCE MAKES A DIFFERENCE
The HeartMate II LVAD is the most widely used and extensively studied LVAD in the world, with more patients treated with the HeartMate II LVAD and multiple clinical data published in top peer-reviewed journals.
PREDICTABLE PERFORMANCE FOR IMPROVED OUTCOMES
HEARTMATE II LVAD SHOWS IMPROVED SURVIVAL OVER TIME IN LVAD TRIALS**
HEARTMATE II LVAD OFFERS PATIENTS LONG-TERM SURVIVAL RATES THAT APPROACH THOSE OF TRANSPLANTATION
HEARTMATE II LVAD PROVIDES SIGNIFICANT IMPROVEMENTS IN FUNCTIONAL CLASS AND QUALITY OF LIFE FOR PATIENTS
NYHA CLASS IMPROVEMENT
More than 80 percent of patients improved to NYHA Class I/II from NYHA Class IIIB/IV by six months, with improvement sustained through 24 months.
6 MINUTE WALK DISTANCE IMPROVEMENT
Distance for patients who could walk at baseline improved to > 340 m from 181 ± 138 m to 225 ± 142 m by six months, with improvement sustained through 24 months.
HEARTMATE II LVAD HAS A CONSISTENT ADVERSE EVENT PROFILE WITH CONTINUED IMPROVEMENTS OVER TIME
Allowing surgeons to implant with confidence, the HeartMate II LVAD offers a unique level of predictability.